George Fromm

George Fromm

Company: Shattuck Labs

Job title: Vice President of Research & Development


Preclinical Development Of A Bi- Functional Sirpa-Fc-CD40L (SL-172154) Fusion Protein Demonstrates Translatable On-Target Pharmacodynamic Activity; And Is Now Being Evaluated In Multiple Human Clinical Trials 4:00 pm

SL-172154, a bi-functional SIRPa-Fc-CD40L fusion protein, can bridge innate and adaptive anti-tumor immunity SIRPa-Fc-CD40L provides simultaneous CD47 checkpoint blockade and antigen presenting cell costimulation via CD40/L; thereby inducing a robust antigen-specific CD8+ T cell anti-tumor response SL-172154 is currently being clinically evaluated in ovarian cancer and head and neck or skin squamous cell carcinomaRead more

day: Clinical Development - Day 1 pm2

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.